About Echo Biotech
Beijing Echo Biotech Co., Ltd. is a biotechnology company focused on the development, scalable manufacturing, and clinical translation of extracellular vesicle technologies, particularly exosomes.
Quick Facts
- Beijing Echo Biotech Co., Ltd. is a biotechnology company focused on the development, scalable manufacturing, and clinical translation of extracellular vesicle technologies, parti…
- 2017: Company founded and entered the exosome field Completed angel round financing Recognized as a "Zhongguancun Golden Seed Enterprise"
- 2018: Secured tens of millions RMB in Pre-A financing Recognized as a "Zhongguancun High-tech Enterprise" Drafted the first domestic expert consensus on exosomes
- 2019: Co-hosted the Exosome Industry Forum with the Chinese Anti-Cancer Association Officially launched exosome research services
- 2020: Co-organized the Exosome Lecture Series with CSEV Recognized as a "National High-tech Enterprise" Partner institutions exceeded 100
- 2021: Completed nearly RMB 100 million in Series A financing Approved to establish a Postdoctoral Research Workstation Employee count exceeded 100 Launched construction of a 3,000…
- 2022: Completed tens of millions RMB in Series A+ financing Comprehensively implemented digital office systems Launched engineered exosome business Supported publication of over 1…
- 2023: Awarded the National "Little Giant" Specialized and Innovative Enterprise title Completed tens of millions RMB in Series A2 financing Launched CRDMO services
- 2024: Participated in a National Key R&D Program project Exosome raw materials obtained the first international dual registration of DMF Type II and INCI Engineered exosome techno…
Page Overview
Beijing Echo Biotech Co., Ltd. (Echo Biotech) is a biotechnology company focused on the development, scalable manufacturing, and clinical translation of extracellular vesicle (EV) technologies, particularly exosomes.
Addressing the critical steps from scientific discovery to product translation, the company has established three core technology platforms: Exoomics®, its exosome multi-omics and research services platform; Echosome®, its engineered exosome technology platfo…
To date, Echo Biotech has established collaborations with more than 2,000 hospitals, universities, research institutions, and industry partners in China and worldwide.
The company has been recognized as a Beijing Specialized, Refined, Distinctive, and Innovative SME and a National High-Tech Enterprise, operates a postdoctoral research workstation, and has completed multiple financing rounds totaling several hundred million…
In engineered exosomes, research from the company's proprietary foundational technology platform was published in the Journal of Extracellular Vesicles, a leading international journal in the EV field.
At the end of 2024, Echo Biotech joined a project under China's National Key R&D Program, "Stem Cell Research and Organ Repair," contributing to the development of extracellular vesicle quality standards, evaluation methods, and reference material systems, an…
Echo Biotech is committed to advancing exosomes from research tools to standardized products and innovative therapies through scalable, evaluable, reproducible, and translatable technology systems, delivering safer, more effective, and more accessible solutio…
Better Life with Exosomes.
Timeline
2017: Company founded and entered the exosome field Completed angel round financing Recognized as a "Zhongguancun Golden Seed Enterprise"
2018: Secured tens of millions RMB in Pre-A financing Recognized as a "Zhongguancun High-tech Enterprise" Drafted the first domestic expert consensus on exosomes
2019: Co-hosted the Exosome Industry Forum with the Chinese Anti-Cancer Association Officially launched exosome research services
2020: Co-organized the Exosome Lecture Series with CSEV Recognized as a "National High-tech Enterprise" Partner institutions exceeded 100
2021: Completed nearly RMB 100 million in Series A financing Approved to establish a Postdoctoral Research Workstation Employee count exceeded 100 Launched construction of a 3,000 m² GMP pilot-scale facility
2022: Completed tens of millions RMB in Series A+ financing Comprehensively implemented digital office systems Launched engineered exosome business Supported publication of over 100 scientific papers
2023: Awarded the National "Little Giant" Specialized and Innovative Enterprise title Completed tens of millions RMB in Series A2 financing Launched CRDMO services
2024: Participated in a National Key R&D Program project Exosome raw materials obtained the first international dual registration of DMF Type II and INCI Engineered exosome technology published in the leading journal JEV Won the Third Prize of Jiangsu Provinc…
2025: Completed over RMB 100 million in Series B financing Advanced more than 10 investigator-initiated clinical studies (IIT) Established multiple exosome technology translation and application centers nationwide Featured in a special report by Beijing Radio…
Honors
National Specialized and Innovative “Little Giant” Enterprise
High-Tech Enterprise
Beijing Specialized and Innovative SME
Postdoctoral Research Workstation
Intellectual Property Pilot Unit
ISO Quality Management System Certification